MDGL
Price
$309.48
Change
-$10.39 (-3.25%)
Updated
Jul 15, 04:15 PM (EDT)
Capitalization
7.1B
22 days until earnings call
SAGE
Price
$9.15
Change
-$0.12 (-1.29%)
Updated
Jul 14 closing price
Capitalization
572.99M
21 days until earnings call
Interact to see
Advertisement

MDGL vs SAGE

Header iconMDGL vs SAGE Comparison
Open Charts MDGL vs SAGEBanner chart's image
Madrigal Pharmaceuticals
Price$309.48
Change-$10.39 (-3.25%)
Volume$5.01K
Capitalization7.1B
Sage Therapeutics
Price$9.15
Change-$0.12 (-1.29%)
Volume$2.23M
Capitalization572.99M
MDGL vs SAGE Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. SAGE commentary
Jul 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and SAGE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 15, 2025
Stock price -- (MDGL: $319.87 vs. SAGE: $9.15)
Brand notoriety: MDGL and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 111% vs. SAGE: 112%
Market capitalization -- MDGL: $7.1B vs. SAGE: $572.99M
MDGL [@Biotechnology] is valued at $7.1B. SAGE’s [@Biotechnology] market capitalization is $572.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.86B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, SAGE is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 6 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 5 bearish.
  • SAGE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +10.62% price change this week, while SAGE (@Biotechnology) price change was -0.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.62%. For the same industry, the average monthly price growth was +18.38%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

SAGE is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.1B) has a higher market cap than SAGE($573M). SAGE YTD gains are higher at: 68.508 vs. MDGL (3.662). SAGE (-358.98M) and MDGL (-376.15M) have comparable annual earnings (EBITDA) . MDGL has more cash in the bank: 843M vs. SAGE (424M). SAGE has less debt than MDGL: SAGE (11.9M) vs MDGL (120M). MDGL has higher revenues than SAGE: MDGL (317M) vs SAGE (47.4M).
MDGLSAGEMDGL / SAGE
Capitalization7.1B573M1,239%
EBITDA-376.15M-358.98M105%
Gain YTD3.66268.5085%
P/E RatioN/AN/A-
Revenue317M47.4M669%
Total Cash843M424M199%
Total Debt120M11.9M1,008%
FUNDAMENTALS RATINGS
MDGL vs SAGE: Fundamental Ratings
MDGL
SAGE
OUTLOOK RATING
1..100
1129
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
32
Undervalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5538
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (32) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDGL (65). This means that SAGE’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for SAGE (100). This means that MDGL’s stock grew somewhat faster than SAGE’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as SAGE (98). This means that MDGL’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as MDGL (55). This means that SAGE’s stock grew similarly to MDGL’s over the last 12 months.

SAGE's P/E Growth Rating (97) in the Pharmaceuticals Other industry is in the same range as MDGL (100). This means that SAGE’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLSAGE
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
81%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRMSX37.71N/A
N/A
T. Rowe Price Emerging Markets Stock
LVPSX94.30N/A
N/A
ProFunds Large Cap Value Svc
ASQAX15.82N/A
N/A
American Century Small Company A
MXMDX21.46N/A
N/A
Empower S&P Mid Cap 400® Index Inv
EWMCX38.38N/A
N/A
Evercore Equity